Pozen tries again to win approval for Trexima

Pozen said it will initiate a toxicity trial of its migraine treatment Trexima on human subjects in an attempt to ease FDA concerns and obtain regulatory approval for the drug. The biotech firm also has sent additional safety data to the FDA in response to an approvable letter the agency issued for Trexima.

View Full Article in:

News & Observer (Raleigh, N.C.), The · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA